/
Metabolic & Endocrine
Obesity
165
Pipeline Programs↗
555
Active Trials↗
139
Companies Involved↗
Obesity is a highly competitive landscape with 165 programs across 139 companies. The most active players are Novo Nordisk, Eli Lilly, Regeneron. 36 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical77
Phase 132
Phase 220
Phase 336
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
110 of 132 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 132 classified programs, each share of the total. Modality classified for 82% of 165 pipeline programs.
Analysis
Trial Status
1,064
clinical trials
Completed438 · 41%
Recruiting264 · 25%
Active, not recruiting142 · 13%
Not yet recruiting124 · 12%
Enrolling by invitation25 · 2%
Terminated24 · 2%
Other47 · 4%
Clinical Trials
Trial Activity
1064 trials
Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Preclinical·NCT06325722·42 enrolled
Children's Growth and Behavior Study
Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT02390765·1,500 enrolled
FutureShape Family: A Randomised Controlled Trial of an Enhanced Family Care Intervention Targeting Intergenerational Obesity
Recruiting·—·Approved·NCT07872904·400 enrolled
Page 1 of 71
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)